# Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

> **NCT01349335** · PHASE2 · COMPLETED · sponsor: **Otsuka Beijing Research Institute** · enrollment: 180 (actual)

## Conditions studied

- Ascites
- Hepatic Cirrhosis

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Tolvaptan
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01349335
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-01
- **Final completion:** 2010-04
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2012-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349335, "Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01349335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*